Magnetic Resonance in the Detection of Breast Cancers of Different Histological Types

Overview

Journal Magn Reson Insights

Publisher Sage Publications

Specialty Radiology

Date 2014 Aug 13

PMID 25114543

Citations 7

Authors

Rebecca M Mayrhofer

Hsiao Piau Ng

Thomas C Putti

Philip W Kuchel

Affiliations

Soon will be listed here.

Abstract

Breast cancer incidence is increasing worldwide. Early detection is critical for long-term patient survival, as is monitoring responses to chemotherapy for management of the disease. Magnetic resonance imaging and spectroscopy (MRI/MRS) has gained in importance in the last decade for the diagnosis and monitoring of breast cancer therapy. The sensitivity of MRI/MRS for anatomical delineation is very high and the consensus is that MRI is more sensitive in detection than x-ray mammography. Advantages of MRS include delivery of biochemical information about tumor metabolism, which can potentially assist in the staging of cancers and monitoring responses to treatment. The roles of MRS and MRI in screening and monitoring responses to treatment of breast cancer are reviewed here. We rationalize how it is that different histological types of breast cancer are differentially detected and characterized by MR methods.

Citing Articles

Radiomic Analysis of Magnetic Resonance Imaging for Breast Cancer with Mutation: A Single Center Study.

Park J, Kwon L, Lee H, Koo T, Suh Y, Kwon M Diagnostics (Basel). 2025; 15(4).

PMID: 40002579 PMC: 11854707. DOI: 10.3390/diagnostics15040428.

"Pulsed Hypoxia" Gradually Reprograms Breast Cancer Fibroblasts into Pro-Tumorigenic Cells via Mesenchymal-Epithelial Transition.

Nushtaeva A, Ermakov M, Abdurakhmanova M, Troitskaya O, Belovezhets T, Varlamov M Int J Mol Sci. 2023; 24(3).

PMID: 36768815 PMC: 9916667. DOI: 10.3390/ijms24032494.

Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma.

Lee J, Jung J, Kim W, Park C, Lee R, Kim H BMC Cancer. 2020; 20(1):934.

PMID: 32993586 PMC: 7526123. DOI: 10.1186/s12885-020-07443-7.

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.

Jones E, Ray K, Li W, Chien A, Mukhtar R, Esserman L NPJ Breast Cancer. 2019; 5:12.

PMID: 31016232 PMC: 6467896. DOI: 10.1038/s41523-019-0107-9.

Discrimination between breast invasive ductal carcinomas and benign lesions by optimizing quantitative parameters derived from dynamic contrast-enhanced MRI using a semi-automatic method.

Yang J, Yin J Int J Clin Oncol. 2019; 24(7):815-824.

PMID: 30810889 DOI: 10.1007/s10147-019-01421-1.

References

Tozaki M, Sakamoto M, Oyama Y, Ouchi T, Kawano N, Suzuki T . Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging. 2008; 28(2):420-7. DOI: 10.1002/jmri.21454. View

Pickles M, Lowry M, Manton D, Gibbs P, Turnbull L . Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005; 91(1):1-10. DOI: 10.1007/s10549-004-5819-2. View

Park S, Moon W, Cho N, Song I, Chang J, Park I . Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2010; 257(1):56-63. DOI: 10.1148/radiol.10092021. View

Sitter B, Lundgren S, Bathen T, Halgunset J, Fjosne H, Gribbestad I . Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2005; 19(1):30-40. DOI: 10.1002/nbm.992. View

Sinha S, Sinha U . Recent advances in breast MRI and MRS. NMR Biomed. 2008; 22(1):3-16. DOI: 10.1002/nbm.1270. View

Sachdev D, Yee D . The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8(3):197-209. DOI: 10.1677/erc.0.0080197. View

Ah-See M, Makris A, Taylor N, Harrison M, Richman P, Burcombe R . Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008; 14(20):6580-9. DOI: 10.1158/1078-0432.CCR-07-4310. View

Yeung D, Cheung H, Tse G . Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results. Radiology. 2001; 220(1):40-6. DOI: 10.1148/radiology.220.1.r01jl0240. View

Vivanco M . Biomarkers in breast cancer. Methods Mol Biol. 2009; 593:137-56. DOI: 10.1007/978-1-60327-194-3_7. View

10.

Sarvazyan A, Egorov V, Son J, Kaufman C . Cost-effective screening for breast cancer worldwide: current state and future directions. Breast Cancer (Auckl). 2009; 1:91-9. PMC: 2613364. DOI: 10.4137/bcbcr.s774. View

11.

Thomas M, Lipnick S, Velan S, Liu X, Banakar S, Binesh N . Investigation of breast cancer using two-dimensional MRS. NMR Biomed. 2008; 22(1):77-91. DOI: 10.1002/nbm.1310. View

12.

Meisamy S, Bolan P, Baker E, Bliss R, Gulbahce E, Everson L . Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology. 2004; 233(2):424-31. DOI: 10.1148/radiol.2332031285. View

13.

Turkbey B, Thomasson D, Pang Y, Bernardo M, Choyke P . The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol. 2009; 16(3):186-92. PMC: 3518910. DOI: 10.4261/1305-3825.DIR.2537-08.1. View

14.

Iima M, Le Bihan D, Okumura R, Okada T, Fujimoto K, Kanao S . Apparent diffusion coefficient as an MR imaging biomarker of low-risk ductal carcinoma in situ: a pilot study. Radiology. 2011; 260(2):364-72. DOI: 10.1148/radiol.11101892. View

15.

Uematsu T, Kasami M . MR imaging findings of benign and malignant circumscribed breast masses: part 1. Solid circumscribed masses. Jpn J Radiol. 2009; 27(10):395-404. DOI: 10.1007/s11604-009-0359-7. View

16.

Santamaria G, Velasco M, Bargallo X, Caparros X, Farrus B, Fernandez P . Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images. Radiographics. 2010; 30(2):533-48. DOI: 10.1148/rg.302095044. View

17.

Lentz M . The role of therapeutic apheresis in the treatment of cancer: a review. Ther Apher. 1999; 3(1):40-9. DOI: 10.1046/j.1526-0968.1999.00147.x. View

18.

Twelves C, Porter D, Lowry M, Dobbs N, Graves P, Smith M . Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy. Br J Cancer. 1994; 69(6):1151-6. PMC: 1969456. DOI: 10.1038/bjc.1994.226. View

19.

Redmond O, Stack J, OConnor N, Carney D, Dervan P, Hurson B . 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn Reson Med. 1992; 25(1):30-44. DOI: 10.1002/mrm.1910250104. View

20.

Partridge S, Rahbar H, Murthy R, Chai X, Kurland B, DeMartini W . Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast-enhanced kinetics. Magn Reson Med. 2011; 65(6):1759-67. PMC: 3201817. DOI: 10.1002/mrm.22762. View